Does a homeopathic ultramolecular dilution of Thyroidinum 30cH affect the rate of body weight reduction in fasting patients? A randomised placebo-controlled double-blind clinical trial.
OBJECTIVE
To test whether an ultramolecular dilution of homeopathic Thyroidinum has an effect over placebo on weight reduction of fasting patients in so-called 'fasting crisis'.


METHODS
Randomised, placebo-controlled, double-blind, parallel group, monocentre study.


METHODS
Hospital for internal and complementary medicine in Munich, Germany.


METHODS
Two hundred and eight fasting patients encountering a stagnation or increase of weight after a weight reduction of at least 100 g/day in the preceding 3 days.


METHODS
One oral dose of Thyroidinum 30cH (preparation of thyroid gland) or placebo.


METHODS
Main outcome measure was reduction of body weight 2 days after treatment. Secondary outcome measures were weight reduction on days 1 and 3, 15 complaints on days 1-3, and 34 laboratory findings on days 1-2 after treatment.


RESULTS
Weight reduction on the second day after medication in the Thyroidinum group was less than in the placebo group (mean difference 92 g, 95% confidence interval 7-176 g, P=0.034). Adjustment for baseline differences in body weight and rate of weight reduction before medication, however, weakened the result to a non-significant level (P=0.094). There were no differences between groups in the secondary outcome measures.


CONCLUSIONS
Patients receiving Thyroidinum had less weight reduction on day 2 after treatment than those receiving placebo. Yet, since no significant differences were found in other outcomes and since adjustment for baseline differences rendered the difference for the main outcome measure non-significant, this result must be interpreted with caution. Post hoc evaluation of the data, however, suggests that by predefining the primary outcome measure in a different way, an augmented reduction of weight on day 1 after treatment with Thyroidinum may be demonstrated. Both results would be compatible with homeopathic doctrine (primary and secondary effect) as well as with findings from animal research.
Schmidt
J M
JM
Krankenhaus für Naturheilweisen, Munich, Germany. josef.m.schmidt@lrz.uni-muenchen.de
Ostermayr
B
B
D000328:Adult; D013956:Antithyroid Agents / Q000008:administration & dosage*; D001835:Body Weight / Q000187:drug effects*; D002908:Chronic Disease / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005215:Fasting; D005260:Female; D005858:Germany; D006705:Homeopathy / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012107:Research Design; D013963:Thyroid Hormones / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome
D013956:Antithyroid Agents; D013963:Thyroid Hormones; C004227:thyroidin